Affordable Access

deepdyve-link
Publisher Website

A phase I clinical trial of irinotecan and carboplatin in patients with extensive stage small cell lung cancer.

Authors
  • Crabb, Simon J
  • Bradbury, Jennifer
  • Nolan, Luke
  • Selman, Diana
  • Muthuramalingam, Sethupathi R
  • Cave, Judith
  • Johnson, Peter W M
  • Ottensmeier, Christian
Type
Published Article
Journal
Chemotherapy
Publisher
S. Karger AG
Publication Date
Jan 01, 2012
Volume
58
Issue
4
Pages
257–263
Identifiers
DOI: 10.1159/000341274
PMID: 22907396
Source
Medline
License
Unknown

Abstract

Irinotecan 60 mg/m2 on days 1 and 8 combined with carboplatin AUC 5 every 21 days is recommended for phase II evaluation. This regimen has clinical activity, acceptable toxicity and greater dose intensity over those currently tested in phase III trials.

Report this publication

Statistics

Seen <100 times